Systemic Treatment – Quality-Based Funding Regimen Request Tracker
The following regimens have been requested to be added to the Systemic Treatment – Quality-Based Procedure (ST-QBP) evidence-informed list. The table includes regimens requested over approximately the last 12 months.
Check Regimen Status Before Submitting a Request
Before requesting a new or modified regimen for funding consideration, search this page for the regimen name to verify whether the regimen is already under review (pending), or has already been approved or not approved.
For information about all other approved regimens, please refer to Funded Evidence-Informed Regimens.
Last Update: January 2026
| ST-QBP REGIMEN REQUEST STATUS TRACKER REGIMEN | DISEASE SITE | INTENT | DRUGS WITHIN THE REGIMENS | STATUS |
|---|---|---|---|---|
| CISP(RT-W)+PEMB | Head and Neck | Adjuvant/Curative | Cisplatin, Pembrolizumab | Approved |
| FLODOCE+DURV; DURV(MNT) | Gastrointestinal | Neoadjuvant/ Adjuvant | Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Durvalumab | Pending |
| CYTA(HD)+QUIZ; QUIZ(MNT) | Hematologic | Curative | Cytarabine, Quizartinib | Approved |
| CISPETOP(5D) | Gynecologic | Palliative | Etoposide, Cisplatin | Approved |
| PACL(W)+PERT+TRAS | Breast | Neoadjuvant | Paclitaxel, Pertuzumab, Trastuzumab | Approved |
| ALEC | Lung | Adjuvant | Alectinib | Approved |
| CRBPGEMC+TORI; TORI(MNT) | Head and Neck | Palliative | Carboplatin, Gemcitabine, Toripalimab | Approved |
| CISPGEMC+TORI; TORI(MNT) | Head and Neck | Palliative | Cisplatin, Gemcitabine, Toripalimab | Approved |
| CISPPEME+AMIV; AMIV(MNT) | Lung | Palliative | Cisplatin, Pemetrexed, Amivantamab | Pending |
| SEVA | Lung | Palliative | Sevabertinib | Pending |
| ACALBEND+RITU | Hematologic | Palliative | Acalabrutinib, Bendamustine, Rituximab | Pending |
| MOSU | Hematologic | Palliative | Mosunetuzumab | Pending |
| CISPETOP(5D) | Genitourinary | Palliative | Cisplatin; Etoposide | Approved |
| LANR (Q2Weeks) | Gastrointestinal | Palliative | Lanreotide | Approved |
| IVOS | Gastrointestinal | Palliative | Ivosidenib | Approved |
| CRBPPACL(W)+RETI; RETI(MNT); | Gastrointestinal | Palliative | Retifanlimab, Carboplatin, Paclitaxel | Approved |
| CISPPEME+PEMB; CRBPPEME+PEMB; PEMB(MNT) | Gastrointestinal (Mesothelioma) | Palliative | Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab | Approved |
| ANASRIBO; EXEMRIBO; LETRRIBO | Breast | Adjuvant | Ribociclib, Anastrazole, Exemestane, Letrozole | Approved |
| MTRX (Alternate Schedule) | Gynecologic | Curative | Methotrexate | Approved |
| SACI | Breast | Palliative | Sacituzumab | Approved |
| ENCO+PEMB | Genitourinary | Palliative | Enfortumab, Pembrolizumab | Approved |
| BEND+BREN | Hematologic | Palliative | Bendamustine, Brentuximab | Approved |
| PEMB; PEMB(RT); CISP(RT)+PEMB; CISP(RT-W)+PEMB; CRBP(RT-3W)+PEMB; CRBPFU(RT)+PEMB | Head and Neck | Adjuvant/Curative | Pembrolizumab, Cisplatin, Carboplatin | Approved |
| MIRV | Gynaecological | Palliative | Mirvetuximab Sorvtansine | Approved |
| CRBPPACL+PEMB; CISPPACL+PEMB; PEMB(MNT) | Gynecologic | Palliative | Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab | Approved |
| NIVL+IPIL; NIVL(MNT) | Gastrointestinal | Palliative | Nivolumab, Ipilimumab | Approved |
| MFOLFOX6+ENCO+CETU | Gastrointestinal | Palliative | Oxaliplatin, Leucovorin, Fluorouracil; Encorafenib, Cetuximab | Approved |
| OXALRALT+BEVA | Gastrointestinal | Palliative | Raltitrexed, Oxaliplatin, Bevacizumab | Approved |
| OXALRALT+ZOLB | Gastrointestinal | Palliative | Raltitrexed, Oxaliplatin, Zolbetuximab | Approved |
| CISPGEMC+DURV; DURV | Genitourinary | Adjuvant/Curative | Durvalumab, Gemcitabine, Cisplatin | Approved |
| CAPEMTMC(RT) | Genitourinary | Adjuvant/Curative | Capecitabine, Mitomycin | Approved |
| FLVSINAVPALB | Breast | Palliative | Inavolisib, Palbociclib, Fulvestrant | Approved |
| RITU(DESENS) | Hematologic | All | Rituximab given using a desensitization protocol | Approved |
| TRAS(DESENS) | Breast, Gastrointestinal | All | Trastuzumab given using a desensitization protocol | Approved |
| CISPPEME+PEMB; CRBPPEME+PEMB; PEMB(MNT) | Lung (Mesothelioma) | Palliative | Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab | Approved |
| LAZE+AMIV | Lung | Palliative | Lazertinib, Amivantamab | Approved |
| TEPO | Lung | Palliative | Tepotinib | Approved |
| ABIRPRED | Genitourinary | Adjuvant/Curative | Abiraterone, Prednisone | Approved |
| CRBPDOCE | Genitourinary | Palliative | Carboplatin, Docetaxel | Approved |
| CRBPPACL+DOST; DOST(MNT) | Gynaecologic | Adjuvant/Curative Palliative | Dostarlimab, Paclitaxel, Carboplatin, | Approved |
| CRBPPACL+DURV; DURV(MNT); OLAP+DURV(MNT) | Gynaecologic | Adjuvant/Curative Palliative | Durvalumab, Carboplatin, Paclitaxel, Olaparaib | Approved |
| BORTDEXA+BELA | Hematology | Palliative | Bortezomib, Dexamethasone, Belantamab | Approved |
| BORTDEXALENA+ISAT | Hematology | Palliative | Isatuximab, Bortezomib, Lenalidomide, Dexamethasone | Approved |
| DEXAPOMA+BELA | Hematology | Palliative | Belantamab, Pomalidomide, Dexamethasone, | Approved |
| IBRU+RITU | Hematology | Palliative | Ibrutinib, Rituximab | Approved |
| TALQ | Hematology | Palliative | Talquetamab | Not Approved |
| EC+PEMB | Breast | Neoadjuvant | Epirubicin, Cyclophosphamide, Pembrolizumab | Approved |
| CRBPDOCE+PEMB | Breast | Adjuvant/Curative | Carboplatin, Docetaxel, Pembrolizumab | Approved |
| RELU | Genitourinary | Palliative | Relugolix | Approved |
| CRBPPACL(W) | Gynaecologic | Adjuvant/Curative Palliative | Carboplatin, Paclitaxel | Approved |
| BLIN(CONS) | Hematologic | Adjuvant/Curative Palliative | Blinatumomab | Approved |
| CHOP+IR-DHAP+R; IBRU(MNT) | Hematologic | Palliative | Ibrutinib | Approved |
| DEXAPOMASELI | Hematologic | Palliative | Selinexor, Pomalidomide, dexamethasone | Approved |
| GEMOX+GLOF; GLOF(MNT) | Hematologic | Palliative | Obinutuzumab, Gemcitabine, Oxaliplatin, Glofitamab | Approved |
| IBRUVENE | Hematologic | Palliative | Ibrutinib, Venetoclax | Approved |
| CRBPPACL+PEMB; PEMB(MNT) | Gynecologic | Adjuvant/Curative Palliative | Carboplatin, Paclitaxel, Pembrolizumab | Approved |
| CRBPPACL(W) | Gynecologic | Adjuvant/Curative | Carboplatin, Paclitaxel | Approved |
| CISP(RT-W)+PEMB; CRBP(RT)+PEMB; PEMB | Gynecologic | Adjuvant/Curative | Pembrolizumab, Cisplatin, Carboplatin | Approved |
| AVD+NIVL | Hematologic | Adjuvant/Curative | Doxorubicin, Vinblastine, Dacarbazine, Nivolumab | Approved |
| BLIN | Hematologic | Adjuvant/Curative Palliative | Blinatumomab | Approved |
| BORTDEXALENA+DARA(SC); LENA+DARA(MNT-SC) | Hematologic | Palliative | Bortezomib, Dexamethasone, Lenalidomide, Daratumumab | Approved |
| BreCADD | Hematologic | Adjuvant/Curative | Brentuximab, Doxorubicin, Cyclophosphamide, Etoposide, Dacarbazine, Dexamethasone | Approved |
| CHP+POLA+RITU | Hematologic | Adjuvant/Curative | Cyclophosphamide, Doxorubicin, Prednisone, Polatuzumab Vedotin, Rituximab | Approved |
| GEMOX+PEG | Hematologic | Adjuvant/Curative | Pegaspargase, Gemcitabine, Oxaliplatin | Approved |
| DOXOTRBC; TRBC(MNT) | Sarcoma | Palliative | Doxorubicin, Trabectedin, Trabecetedin Mainetance | Approved |
| ABIROLAPPRED | Genitourinary | Palliative | Abiraterone, Olaparib, Prednisone/Prednisolone | Approved |
| BELZ | Gastrointestinal | Palliative | Belzutifan | Approved |
| NIVL+IPIL; NIVL(MNT) | Skin | Palliative | Nivolumab, Ipilimumab | Approved |
| CALA(DESENS) | Hematologic | Curative | Calaspargase Pegol | Approved |
| MFOLFOX6+ZOLB, XELOX+ZOLB; CAPECISP+ZOLB; CAPECRBP+ZOLB; CISPFU+ZOLB; CRBPFU+ZOLB; ZOLB(MNT); CAPE+ZOLB(MNT); FU+ZOLB(MNT) | Gastrointestinal | Palliative | Zolbituximab, Chemo backbone | Approved |